Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.37 |
| ▸ | SYK | P43405 | 9/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13527004 | 0.90 | BTK (0.36) | BTKSYKTNKS | |
| SCHEMBL13531801 | 0.85 | BTK (0.40) | BTKSYKTNKS | |
| SCHEMBL13526978 | 0.79 | BTK (0.45) | BTK | |
| SCHEMBL13527017 | 0.77 | BTK (0.61) | BTK | |
| SCHEMBL13531799 | 0.76 | BTK (0.39) | BTKSYKTNKS | |
| SCHEMBL13526956 | 0.74 | BTK (0.53) | BTK | |
| SCHEMBL13526979 | 0.71 | BTK (0.38) | BTKTNKS | |
| SCHEMBL13547730 | 0.70 | MEN1 (0.36) | TNKS | |
| SCHEMBL13527018 | 0.70 | BTK (0.52) | BTK | |
| SCHEMBL13526953 | 0.67 | BTK (0.44) | BTKTNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324211-B2 | 6-Dimethylamino-2-(2-hydroxymethyl-3-{8-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-imidazo[1,2-b]pyridazin-6-yl }-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; asthma, lupus ; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | BTK 1/4885SYK 2/4885TNKS 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.